Drug Profile
Research programme: B-Raf kinase inhibitors - Eli Lilly and Company
Latest Information Update: 09 May 2022
Price :
$50
*
At a glance
- Originator Deciphera Pharmaceuticals
- Developer Deciphera Pharmaceuticals; Eli Lilly and Company
- Class Small molecules
- Mechanism of Action Proto oncogene protein b raf inhibitors; Raf kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
- No development reported Malignant melanoma
Most Recent Events
- 04 May 2022 Deciphera Pharmaceuticals intends to nominate candidate from pan-RAF inhibitor research program in 2022
- 14 Apr 2022 Preclinical development is ongoing for Solid tumours in USA (Deciphera Pharmaceuticals pipeline, April 2022)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Malignant-melanoma in USA